The aim of this new statement is to provide a comprehensive and evidence-based review of
the scientific data evaluating the use of telemedicine for stroke care delivery and to provide …

Objective: To describe the role of adhesion molecules in ischemic stroke. Methods: A
PubMed search of literature pertaining to this study was conducted in April 2008 using …

Stroke is a primary cause of death and disability worldwide, while effective and safe drugs
remain to be developed for its clinical treatment. Herein, we report bioactive nanoparticle …

Background Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the
only approved pharmacological treatment for acute ischemic stroke. We studied whether …

Background and hypothesis Thrombolytic therapy with tissue plasminogen activator is
effective for acute ischaemic stroke within 4· 5 h of onset. Patients who wake up with stroke …

Background Pneumonia is a major risk factor of death after acute stroke. In a mouse model,
preventive antibacterial therapy with moxifloxacin not only prevents the development of post …

Thromboembolism is a severe complication in atrial fibrillation. This overview presents
thromboembolic disease as a single entity, ranging from stroke through mesenteric ischemia …

Experimental research into brain ischemia contributes substantially to the understanding of
ischemic injury mechanisms but suffers from its limited relevance for clinical treatment …

Background: Ischemic stroke is a leading cause of morbidity and mortality worldwide and
recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic …

Reperfusion therapy for acute stroke has evolved from the initial use of intravenous tissue
plasminogen activator (tPA) within 3 hours of symptom onset to more recent guideline …